Karyopharm Therapeutics Inc.
KPTI
$7.46
$1.1518.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.77% | 1.19% | -0.55% | 1.77% | -0.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.77% | 1.19% | -0.55% | 1.77% | -0.23% |
| Cost of Revenue | -108.93% | -46.55% | 21.55% | 228.27% | 191.79% |
| Gross Profit | 6.74% | 4.29% | -1.32% | -17.11% | -20.38% |
| SG&A Expenses | -9.39% | -9.78% | -12.47% | -14.64% | -14.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.73% | -4.32% | -3.95% | -0.20% | 0.70% |
| Operating Income | 12.02% | 10.17% | 7.79% | 2.43% | -1.76% |
| Income Before Tax | -37.86% | 57.19% | 46.51% | 37.50% | 36.56% |
| Income Tax Expenses | -101.79% | -93.53% | -82.35% | 11.28% | -6.35% |
| Earnings from Continuing Operations | -37.43% | 57.27% | 46.60% | 37.41% | 36.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.43% | 57.27% | 46.60% | 37.41% | 36.50% |
| EBIT | 12.02% | 10.17% | 7.79% | 2.43% | -1.76% |
| EBITDA | 12.04% | 10.20% | 7.68% | 2.26% | -2.03% |
| EPS Basic | -23.13% | 56.42% | 50.04% | 43.34% | 46.11% |
| Normalized Basic EPS | 16.04% | 32.54% | 20.24% | 17.58% | 22.84% |
| EPS Diluted | 14.08% | 27.80% | 22.01% | 16.99% | 22.69% |
| Normalized Diluted EPS | 13.26% | 35.47% | 23.21% | 20.33% | 25.32% |
| Average Basic Shares Outstanding | 8.92% | 8.74% | 6.69% | 10.25% | 17.06% |
| Average Diluted Shares Outstanding | 1.63% | 16.02% | 13.99% | 17.98% | 25.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |